Is there a patent “amino acid sequence listing” for blinatumomab?
Yes. Blinatumomab is a recombinant bispecific T‑cell engager, and patent filings that claim blinatumomab (or related constructs) typically include the relevant amino‑acid sequence (often as a sequence listing) so examiners and courts can identify exactly what is covered.
Which patent should I look for to get the blinatumomab amino-acid sequence listing?
To find the correct sequence listing, you need the specific patent family or application because different filings can include different numbering/construct details (for example, signal peptide, mature protein region boundaries, linkers, tags, or whether the listing is “SEQ ID NO” for one chain vs the full construct).
If you share the patent number (publication number like WO…/EP…/US… and, ideally, the specific claim or the family member), I can point you to exactly where the sequence listing appears and how to match “SEQ ID NO” entries to the blinatumomab chains.
Where in a patent document is the sequence listing usually located?
Most patent applications include an attached “Sequence Listing” section or a separate ST‑file/annex in the publication. Common patterns:
- A “Sequence Listing” appendix with “SEQ ID NO: …” entries
- References in the description/claims that link to those “SEQ ID NO” identifiers
- Different chain listings for the two binding domains (or a single contiguous construct listing)
What exactly might be listed for blinatumomab (and why details can differ)?
Patent sequence listings can vary based on how the construct is defined:
- One entry for each polypeptide chain (e.g., the two halves of the bispecific)
- One entry for the overall fusion construct
- Inclusion or exclusion of the N‑terminal signal peptide (patents often list the expressed/mature sequence, but not always)
- Exact linker and hinge/constant-region boundaries
So two patents can both be “about blinatumomab” but still show different sequence numbering or slightly different listed regions.
Can you provide the blinatumomab amino-acid sequence directly?
I can, but I need one missing piece: which exact construct definition you want (the whole bispecific fusion or the individual component chains), and which jurisdiction/family you mean. Different sequence listings can map to different “SEQ ID NO” entries even within the same overall product.
If you paste the patent publication number(s) you’re working from, I’ll extract the sequence listing identifiers (SEQ ID NO) and tell you which entries correspond to blinatumomab’s amino‑acid sequence(es).
Quick next step
Send either:
- The patent publication number (example format: WO20xx/xxxxxx, US20xx/xxxxxxx, EPxxxxxxx), or
- A link or the text around “SEQ ID NO” / “Sequence Listing,”
and tell me whether you want the listing for the full construct or for each chain.